CAR-T Cell Study for Advanced HER2-Positive Cancers
Part of Cancer, Digestive system, Skin clinical trials.
This early-stage trial tests a new type of immune cell therapy called CAR-T cells, which are designed to recognize and attack cancer cells that have a protein called HER2. The cells are made from your own immune cells, trained in the laboratory, and given back to you. The study evaluates how safe the treatment is and whether it can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced or metastatic cancer (spread to other parts of your body) that is resistant to standard treatments, such as breast, gastric, endometrial, or certain other solid tumors.
- Your cancer must test positive for HER2 protein expression (a specific score on a lab test).
- You must be in good overall health with adequate organ function (liver, kidney, heart, lungs, blood counts) as confirmed by blood tests and heart/lung function tests.
- You cannot have active infections (including HIV, hepatitis B/C, TB, or others), untreated brain metastases, or certain other cancers in the past 3 years.
- You must stop most anti-cancer treatments at least 4 weeks before starting the study therapy.
- If you can have children, you must use highly effective birth control during the study and for 12 months after the cell infusion.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests CAR T cells made from your own immune cells to target advanced breast cancer. The cells are designed to recognize a specific cancer marker (called MUC1*), with the goal of shrinking tumors or keeping them under control.
This early-phase trial tests CAR-T cells designed to attack tumors that have high HER2 and PD-L1. It may help people with certain solid cancers that have not responded well to standard treatment.
This study tests a new type of cell therapy called anti-HER2-CAR-T for people with advanced HER2-positive solid tumors (like breast, stomach, or colon cancer) whose cancer has not responded to other treatments. The therapy uses your own immune cells engineered to target and kill cancer cells.
This trial tests a new type of immunotherapy called CAR-T cells that are designed to attack cancer cells that have a high amount of a protein called HER2. It is for people with advanced solid tumors (like certain breast, stomach, or lung cancers) that have not responded to standard treatments.
This trial tests a new type of immune cell therapy (CAR T cells) that targets two markers on cancer cells: TRAIL-R2 and HER2. It is for people with advanced or recurrent HER2-positive breast cancer that has not been stopped by standard treatment.
This trial tests an experimental 'off-the-shelf' CAR-T cell therapy (called FT825/ONO-8250) that targets a protein called HER2 found on some solid tumors. It may be given alone or with other antibodies to help fight advanced cancer that has not responded to standard treatments.
Hear when a new Metastatic Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.